Document is current

Article History

Received: 26 June 2025

Revised: 1 October 2025

Accepted: 27 November 2025

First Online: 12 February 2026

Competing interests

: FSK, AC, RBD, CW, NA, and KLS are employees of Resmed. JLP is supported by the French National Research Agency (ANR) in the framework of the “FRANCE 2030” program, the “e-health and integrated care” chair of Grenoble Alpes University Foundation and “Sleep Health-AI chair” in “MIAI Cluster” of artificial intelligence (ANR-23-IACL-0006). JLP reports income related to medical education from RESMED, SEFAM, Zoll-Respicardia, Eli Lilly, Idorsia, Pharmanovia and Bioprojet. PAC reports having an appointment to an endowed academic Chair at the University of Sydney that was established by Resmed funding, has received research support from Resmed and SomnoMed, and is a consultant to Resmed, SomnoMed, Sunrise Medical, and Eli Lilly. SHM, BS, SRB and KCW are employees of Boston Strategic Partners, funded by Resmed. LW and CK are independent statisticians, funded by Resmed. TK reports project funding from the Canadian Institute of Health Research and CHEST Foundation. DAJ has received consultancy fees from Idorsia. RH has received speaker or consultancy fees from Resmed, Jazz Pharmaceuticals, Inspire Medical Systems, Bioprojet, Philips, Merck, Nyxoah, Medtronic, Nestlé and Löwenstein. CHL has no conflicts to declare. AM is funded by the National Institutes of Health (NIH). AM also reports income related to medical education from Livanova, Jazz Pharmaceuticals, Zoll and Eli Lilly. Resmed provided a philanthropic donation to UC San Diego, but AM has not received personal income from Resmed or medXcloud.